Cargando…

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead

Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), though uncommon, presents a considerable therapeutic challenge with poor long-term outcomes. Currently, tyrosine kinase inhibitors are the mainstay of treatment for advanced RAIR-DTC patients. However, these agents are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satapathy, Swayamjeet, Bal, Chandrasekhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315044/ https://www.ncbi.nlm.nih.gov/pubmed/35903277 http://dx.doi.org/10.3389/fendo.2022.924841

Ejemplares similares

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Insulin-Like Peptide Signaling in Mosquitoes: The Road Behind and the Road Ahead
por: Sharma, Arvind, et al.
Publicado: (2019)

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead
por: Colao, Annamaria, et al.
Publicado: (2020)

A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases
por: Kanankulam Velliangiri, Sivasankar, et al.
Publicado: (2023)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer
por: Ahn, Byeong-Cheol
Publicado: (2016)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
por: Damle, Nishikant Avinash, et al.
Publicado: (2012)

NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer
por: Koehler, Viktoria Florentine, et al.
Publicado: (2023)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Editorial: Immune dysfunction in nephrotic syndrome - recent advances and new roads ahead
por: Seitz-Polski, Barbara, et al.
Publicado: (2022)

Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult
por: Zhao, Xianlan, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

The road ahead
Publicado: (2001)

Rituximab in Pemphigus: Road Covered and Challenges Ahead
por: Vinay, Keshavamurthy, et al.
Publicado: (2018)

Modern India and Dietary Calcium Deficiency—Half a Century Nutrition Data—Retrospect–Introspect and the Road Ahead
por: Harinarayan, Chittari Venkata, et al.
Publicado: (2021)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
por: Damle, Nishikant, et al.
Publicado: (2011)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Public Health Surveillance: Challenges and Solutions for the Road Ahead
por: Nanda, Lipika, et al.
Publicado: (2015)

THE ROLE AND ROAD AHEAD
por: Kumar, K.A.
Publicado: (2001)

Periodontology - The road ahead
por: Thomas, Biju
Publicado: (2014)

JCAS: The Road Ahead
por: Majid, Imran
Publicado: (2017)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead
por: Syed, Khalid Ali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ftq5ad6tetqb78dgdeasrmud7f